A Phase 2 interventional study of TAF and TDF in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 1 site in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-08.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.
Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 19th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 2nd registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–70
First People's Hospital of Hangzhou · Sites in China
Ages 20–40 · Women only
Jidong Jia · Sites in China
Ages 18–69
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 20+
The Task Force for Global Health · Sites in Thailand
Healthy volunteers
By country, each count listing its studies:
tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 1 · Phase 4 14
First in 2012; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 124 across the 26 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 26 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 23rd largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2016, is one of 15 in phase 2, and was the 26th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing tenofovir alafenamide in Hepatitis B, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07203118Phase 3Xi'an Xintong Pharmaceutical Research Co.,Ltd.A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, from their registry updates:
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)-containing regimens at Week 24 in participants with chronic hepatitis B virus (HBV) infection and Stage 2 or greater chronic kidney disease who have received a liver transplant.
Key Inclusion Criteria:
Key Exclusion Criteria:
Participants meeting any of the following laboratory parameters at screening:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAF 25 mg once daily for 48 weeks
Drug: TAF
TDF alone or in combination with other approved antivirals per local practice for 48 weeks
Drug: TDF · Drug: Other approved antivirals
After Week 48, participants will be eligible to receive TAF 25 mg once daily for an additional 144 weeks.
Drug: TAF
Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
Time frame: Baseline, Week 24
Percentage of Participants With HBV DNA < 20 IU/mL at Week 24
Time frame: Week 24
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Hip BMD at Week 48
Time frame: Baseline, Week 48
Percent Change From Baseline in Spine BMD at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Spine BMD at Week 48
Time frame: Baseline, Week 48
Change From Baseline in Serum Creatinine at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Serum Creatinine at Week 48
Time frame: Baseline, Week 48
Change From Baseline in Serum eGFR_CKD-EPI at Week 48
Time frame: Baseline, Week 48
Percentage of Participants With HBV DNA < 20 IU/mL at Week 48
Time frame: Week 48
Participants were enrolled at a study site in New Zealand. The first participant was screened on 16 September 2016. The last study visit occurred on 05 May 2021.
| Milestone | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Started | 26 | 25 |
| Completed | 26 | 24 |
| Not completed | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Milestone | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Started | 26 | 24 |
| Completed | 23 | 23 |
| Not completed | 3 | 1 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 1 |
| mL/min/1.73 m^2 | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation | 2.13 ± 6.011 | 1.87 ± 6.553 |
| percentage of participants | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Percentage of Participants With HBV DNA < 20 IU/mL at Week 24 | 100.0 | 100.0 |
| percent change | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24 | 0.478 ± 1.6342 | 0.452 ± 2.1380 |
| percent change | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Percent Change From Baseline in Hip BMD at Week 48 | 1.253 ± 1.9774 | -0.413 ± 2.6361 |
| percent change | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 24 | 0.799 ± 2.5563 | -0.188 ± 2.5890 |
| percent change | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 48 | 1.454 ± 4.5405 | -1.082 ± 3.0031 |
| mg/dL | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 24 | -0.043 ± 0.1434 | -0.040 ± 0.1623 |
| mg/dL | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 48 | -0.052 ± 0.2233 | -0.058 ± 0.2158 |
| mL/min/1.73 m^2 | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Change From Baseline in Serum eGFR_CKD-EPI at Week 48 | 3.01 ± 9.385 | 2.09 ± 9.209 |
| percentage of participants | TAF 25 mg | TDF-Containing Regimens |
|---|---|---|
| Percentage of Participants With HBV DNA < 20 IU/mL at Week 48 | 100.0 | 88.0 |
Collected over All-Cause Mortality: Randomization up to last follow up visit (maximum 236.7 weeks); Adverse Events: First dose date up to last dose date plus 30 days (maximum 225.9 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Phase: TAF 25 mg | 0/26 (0%) | 3/26 (11.5%) | 19/26 (73.1%) |
| Randomized Phase: TDF-Containing Regimens | 1/25 (4%) | 7/25 (28%) | 17/25 (68%) |
| OLE Phase: TAF 25 mg From TAF | 2/26 (7.7%) | 8/26 (30.8%) | 22/26 (84.6%) |
| OLE Phase: TAF 25 mg From TDF | 0/24 (0%) | 8/24 (33.3%) | 21/24 (87.5%) |
| Event | Randomized Phase: TAF 25 mg | Randomized Phase: TDF-Containing Regimens | OLE Phase: TAF 25 mg From TAF | OLE Phase: TAF 25 mg From TDF |
|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/26 | 0/25 | 1/26 | 4/24 |
| Atrial fibrillationCardiac disorders | 0/26 | 0/25 | 0/26 | 2/24 |
| DiarrhoeaGastrointestinal disorders | 0/26 | 0/25 | 0/26 | 2/24 |
| Lower respiratory tract infectionInfections and infestations | 2/26 | 0/25 | 1/26 | 2/24 |
| UrosepsisInfections and infestations | 0/26 | 0/25 | 0/26 | 2/24 |
| CholangitisHepatobiliary disorders | 1/26 | 2/25 | 2/26 | 1/24 |
| CellulitisInfections and infestations | 0/26 | 1/25 | 2/26 | 1/24 |
| PneumoniaInfections and infestations | 0/26 | 1/25 | 2/26 | 0/24 |
| AnaemiaBlood and lymphatic system disorders | 0/26 | 0/25 | 0/26 | 1/24 |
| ColitisGastrointestinal disorders | 0/26 | 0/25 | 0/26 | 1/24 |
| Event | Randomized Phase: TAF 25 mg | Randomized Phase: TDF-Containing Regimens | OLE Phase: TAF 25 mg From TAF | OLE Phase: TAF 25 mg From TDF |
|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 2/26 | 5/25 | 1/26 | 2/24 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/26 | 2/25 | 5/26 | 1/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/26 | 2/25 | 5/26 | 3/24 |
| Back painMusculoskeletal and connective tissue disorders | 4/26 | 1/25 | 1/26 | 1/24 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/26 | 0/25 | 4/26 | 0/24 |
| HeadacheNervous system disorders | 4/26 | 2/25 | 0/26 | 0/24 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 0/26 | 0/25 | 0/26 | 3/24 |
| LethargyNervous system disorders | 2/26 | 2/25 | 2/26 | 3/24 |
| PyrexiaGeneral disorders | 3/26 | 3/25 | 0/26 | 0/24 |
| Abdominal distensionGastrointestinal disorders | 3/26 | 1/25 | 0/26 | 0/24 |
Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | TAF 25 mg | TDF-Containing Regimens | Total |
|---|---|---|---|
| Mean | 58 ± 12.6 | 62 ± 8.3 | 60 ± 10.8 |
| Sex: Female, Male(Participants) | TAF 25 mg | TDF-Containing Regimens | Total |
|---|---|---|---|
| Female | 10 | 3 | 13 |
| Male | 16 | 22 | 38 |
| Ethnicity (NIH/OMB)(Participants) | TAF 25 mg | TDF-Containing Regimens | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 26 | 25 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | TAF 25 mg | TDF-Containing Regimens | Total |
|---|---|---|---|
| Race — Asian | 7 | 10 | 17 |
| Race — Black or African American | 1 | 0 | 1 |
| Race — Native Hawaiian or Pacific Islander | 15 | 12 | 27 |
| Race — White | 2 | 3 | 5 |
| Race — Other | 1 | 0 | 1 |
| Region of Enrollment(Participants) | TAF 25 mg | TDF-Containing Regimens | Total |
|---|---|---|---|
| New Zealand | 26 | 25 | 51 |
| HBV Deoxy Ribonucleic Acid (DNA)(International unit per mL (IU/mL)) | TAF 25 mg | TDF-Containing Regimens | Total |
|---|---|---|---|
| Mean | 19.0 ± 0.00 | 19.0 ± 0.00 | 19.0 ± 0.00 |
| eGFR by CKD-EPI Creatinine(mL/minute/1.73 square meter(m^2)) | TAF 25 mg | TDF-Containing Regimens | Total |
|---|---|---|---|
| Median | 52.3 ± 12.31 | 52.4 ± 12.74 | 52.4 ± 12.40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Sep 2016 to primary completion in Feb 2018, 16 months.
Results were first posted in Feb 2019, 1 year after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 16 months is below that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir alafenamide